Jefferies has initiated Krystal Biotech at buy citing growth in sales of Vyjuvek (beremagene geperpavec), a gene therapy for ...

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy ...

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...

According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...

Investment analysts at Chardan Capital issued their FY2026 EPS estimates for Krystal Biotech in a research note issued to ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...

(RTTNews) - Krystal Biotech, Inc. (KRYS) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval ...

PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the ...